WallStSmart

Boston Scientific Corp (BSX)vsWarner Bros Discovery Inc (WBD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Warner Bros Discovery Inc generates 81% more annual revenue ($37.30B vs $20.61B). BSX leads profitability with a 17.3% profit margin vs 1.9%. BSX appears more attractively valued with a PEG of 0.68. BSX earns a higher WallStSmart Score of 71/100 (B).

BSX

Strong Buy

71

out of 100

Grade: B

Growth: 8.0Profit: 7.0Value: 5.3Quality: 5.5
Piotroski: 4/9

WBD

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 4.5Value: 5.7Quality: 4.3
Piotroski: 4/9Altman Z: 0.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-22.6%)

Margin of Safety

-22.6%

Fair Value

$46.16

Current Price

$53.93

$7.77 premium

UndervaluedFair: $46.16Overvalued
WBDUndervalued (+60.6%)

Margin of Safety

+60.6%

Fair Value

$71.08

Current Price

$27.11

$43.97 discount

UndervaluedFair: $71.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$84.08B9/10

Large-cap with strong market position

PEG RatioValuation
0.688/10

Growing faster than its price suggests

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

WBD3 strengths · Avg: 9.0/10
EPS GrowthGrowth
226.7%10/10

Earnings expanding 226.7% YoY

Market CapQuality
$67.99B9/10

Large-cap with strong market position

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Areas to Watch

BSX0 concerns · Avg: 0/10

No major concerns identified

WBD4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.1%3/10

ROE of 2.1% — below average capital efficiency

Profit MarginProfitability
1.9%3/10

1.9% margin — thin

PEG RatioValuation
216.922/10

Expensive relative to growth rate

Revenue GrowthGrowth
-5.7%2/10

Revenue declined 5.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : WBD

The strongest argument for WBD centers on EPS Growth, Market Cap, Price/Book.

Bear Case : BSX

No major red flags identified for BSX, but monitor valuation.

Bear Case : WBD

The primary concerns for WBD are Return on Equity, Profit Margin, PEG Ratio. Thin 1.9% margins leave little buffer for downturns.

Key Dynamics to Monitor

BSX profiles as a mature stock while WBD is a value play — different risk/reward profiles.

WBD carries more volatility with a beta of 1.57 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (71/100 vs 51/100), backed by strong 17.3% margins and 11.6% revenue growth. WBD offers better value entry with a 60.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Warner Bros Discovery Inc

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Warner Bros. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?